Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 4/10/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Paul S. Bernstein

Wrong Dr. Paul S. Bernstein?

Scientific Advisory Board Member

Phone: (281) ***-****  HQ Phone
Email: p***@***.com
Local Address:  United States
ScienceBased Health
500 Century Plaza Drive Suite 100
Houston , Texas 77073
United States

Company Description: ScienceBased Health, a privately held company, develops and markets evidence-based nutraceuticals for eye health. The formulations, created by leading physicians,...   more

Employment History

  • Professor of Ophthalmology and Visual Sciences
    University of Utah School of Medicine
  • Researcher and Assistant Professor of Ophthalmology
    University of Utah School of Medicine
  • Katra JV Partner
    Moran Eye Center
  • Tenured Associate Professor of Ophthalmology and Visual Sciences In the Retina Division
    Moran Eye Center
  • Retina Specialist
    Moran Eye Center
  • Mary Boesche Professor of Ophthalmology and Visual Sciences
    Moran Eye Center of the University of Utah
  • Member, Faculty
    Moran Eye Center of the University of Utah
  • Member, Moran Eye Center
    University of Utah
  • Assistant Professor of Ophthalmology and Visual Sciences
    University of Utah
  • Associate Professor of Ophthalmology
    University of Utah

Board Memberships and Affiliations


  • MD
    University of Utah School of Medicine
  • PhD Mohsen Sharifzadeh
  • PhD Judith E. A. Warner
  • MD Werner Gellerman
  • PhD
  • M.D.
  • Ph.D.
  • MD
  • MD
    Moran Eye Center University of Utah School of Medicine Himalayan Cataract Project
  • PhD Mark S. Blumenkranz
  • MD David S. Boyer
143 Total References
Web References
MacularProtect Plus: AREDS Vitamins | Beta-Carotene Free, 10 April 2015 [cached]
Related Information: Read / listen to an interview with Paul Bernstein, MD, PhD on the Role of Lutein & zeaxanthin in Macular Health
Q: Why is purified lutein (ie: FloraGlo®) better than lutein esters (ie: from marigold)?, 8 May 2014 [cached]
Read an interview with ScienceBased Health Science Advisory Board Member, Paul S. Bernstein, MD, PhD, on the role of lutein in macular health. Listen to the audio version!
"I tell my patients that fruit ..., 8 Oct 2015 [cached]
"I tell my patients that fruit and vegetable consumption are very important for eye health -- this study validates that notion," said Dr. Paul Bernstein, a professor of ophthalmology and visual sciences at the University of Utah School of Medicine in Salt Lake City.
Age-related macular degeneration (AMD) is one of the most common causes of vision loss, especially in the elderly. It affects the macula, the center part of the retina, and can lead to declines in sharp central vision and even blindness, experts say.
Scientists have already linked a variety of factors to the condition including genetics, smoking and nutrition, said Bernstein, who was not involved in the new study. However, treatment for AMD may be limited depending on the type of macular degeneration that a person develops, he said.
Lutein is found in eggs and dark leafy vegetables including broccoli, kale and spinach, Bernstein said. Zeaxanthin is harder to find in the diet, he said, but you can get it from corn, orange peppers and goji berries.
Bernstein cautioned that the study has some weaknesses. It's based on people's recollections of their diets, he said, and doesn't examine the levels of the carotenoids that actually made it into their bodies and eyes. Still, he praised the research.
Would carotenoid supplements help? Bernstein said he often recommends nutritional supplements to people with intermediate and advanced forms of macular degeneration, but it's not proven if they'll help people who may be at risk for the condition.
However, he said, a diet high in fruits and vegetables is important, especially colorful vegetables. Consume several servings a day, he advised.
"The people who are only consuming two servings a day are the ones we worry about," Bernstein said.
MDP: Macular Degeneration Help Center, 30 Sept 1999 [cached]
A new testA novel approach was presented this week by Paul S. Bernstein, M.D., Ph.D., a researcher and Assistant Professor of Ophthalmology at University of Utah School of Medicine.Together with his colleagues, Werner Gellermann, Ph.D. and Robert McClane, he developed a technique to measure the carotenoids in the living eye.A device called a Raman spectroscope requires the patient to look into a test light for just one second.The light is slightly absorbed by the eye and then scattered or reflected back to the equipment.The reflected light can be analyzed for a variety of carotenoids, including lutein and zeaxanthin, because they each have a very specific "signature", originating from vibrations within their molecular structure.Clinical trials of this new technique will begin later this year.According to Dr. Bernstein, "Ultimately, our hope is that this technology will become as commonplace as measurement of intraocular pressure and visual fields for the assessment of risk for glaucoma."If a patient has low levels of macular pigment, they would be encouraged to increase consumption of lutein and zeaxanthin.Their eyes could then be assessed with follow-up tests.The device also has the potential to monitor patients participating in long term studies on dietary supplementation.Then, we'll have a clear answer to the question, "Do vitamins help?"Dr. Bernstein presented at the Science Writers Seminar, sponsored by Research to Prevent Blindness, which was held recently in Los Angeles.
CIBA Vision and QLT Announce New Program For Visudyne Therapy
Clinical Trial Offers Additional, Controlled Access to Therapy Prior To Regulatory Approval.ATLANTA and VANCOUVER, British Columbia, Sept. 13 /PRNewswire/ -- CIBAVision, the eye care unit of Novartis AG, and QLT PhotoTherapeutics (Nasdaq: QLTI - news) announced today the initiation of a Treatment-Investigational New Drug (T-IND) clinical program for Visudyne therapy for the treatment of the wet form of age-related macular degeneration (AMD).The program, for which enrollment began September 15, will provide Visudyne therapy within a controlled, clinical setting, prior to regulatory approval, to a certain number of patients who meet specific eligibility criteria.The T-IND clinical program will allow the treatment of up to 4,000 patients.Treatment will take place at approximately 200 sites across the U.S. and Canada, each enrolling up to 20 patients at each site.In a T-IND protocol, the U.S. Food and Drug Administration (FDA) allows drug developers to provide pre-approval access to experimental drugs that are intended to treat serious or life-threatening conditions for which there are no satisfactory treatments and provide additional safety information in a larger cohort of patients than were treated in initial phase III trials."Initiating a T-IND program allows us to offer Visudyne therapy immediately to a broader number of patients most in need of a treatment for this devastating disease prior to regulatory approval," said Luzi von Bidder, President of CIBA Vision's Worldwide Ophthalmics Business Unit.
About Us, 10 April 2015 [cached]
Paul S. Bernstein, MD, PhD
Paul S. Bernstein, MD, PhD is a tenured Associate Professor of Ophthalmology and Visual Sciences in the Retina Division at the Moran Eye Center, University of Utah School of Medicine. Dr. Bernstein graduated summa cum laude from Harvard University, where he also received his MD and PhD in pharmacology. After interning at New England Deaconess Hospital, he completed an Ophthalmology residency and a fellowship in retinal cell biology at the Jules Stein Eye Institute of UCLA School of Medicine, followed by a fellowship in vitreoretinal surgery and research at the Massachusetts Eye and Ear Infirmary. During his residency in Ophthalmology at Jules Stein, he was a recipient of the Jules Stein Resident Research Award. Long interested in macular pigments, Dr. Bernstein has pioneered a method for measuring carotenoid pigment levels. Along with his colleagues, he holds several patents on the non-invasive resonance Raman imaging method for quantifying pigments in the living human macula, and has authored numerous papers on that topic. In addition, Dr. Bernstein's interests include the ocular effects of oxidative stress, and the relationships between dietary carotenoid intake, optical density of the macula and the risk of age-related macular degeneration. Dr. Bernstein is the recipient of numerous awards and grants, and is extensively published.
View / Listen to an interview with Paul Bernstein, MD, PhD on the Role of Lutein & zeaxanthin in Macular Health
ScienceBased Health Announces Appointment of Paul Bernstein, MD, PhD to Scientific Advisory Board
Other People with the name "Bernstein":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.